Reassembly of enzymes from peptide fragments has been used as a strategy for understanding the evolution, folding, and role of individual subdomains in catalysis and regulation of activity. We demonstrate an oligomerization-assisted enzyme reassembly strategy whereby fragments are covalently linked to independently folding and interacting domains whose interactions serve to promote efficient refolding and complementation of fragments, forming active enzyme. We show that active murine dihydrofolate reductase (E.C. 1.5.1.3) can be reassembled from complementary N-and C-terminal fragments when fused to homodimerizing GCN4 leucine zipper-forming sequences as well as heterodimerizing protein partners. Reassembly is detected by an in vivo selection assay in Escherichia coli and in vitro. The effects of mutations that disrupt fragment affinity or enzyme activity were assessed. The steady-state kinetic parameters for the reassembled mutant (Phe-31 3 Ser) were determined; they are not significantly different from the full-length mutant. The strategy described here provides a general approach for protein dissection and domain swapping studies, with the capacity both for rapid in vivo screening as well as in vitro characterization. Further, the strategy suggests a simple in vivo enzyme-based detection system for protein-protein interactions, which we illustrate with two examples: ras-GTPase and raf-ras-binding domain and FK506-binding proteinrapamycin complexed with the target of rapamycin TOR2.
Protein fragment complementation studies have been used to address a number of important questions including gene structure (1) , the role of primary sequence in determining the tertiary structure of proteins (2) , protein folding (3, 4) , and the role of tertiary structure elements in enzyme catalysis (5) to probe macromolecular assembly (6) and to test theories of protein evolution (7) . Novel applications of fragment complementation also have been suggested, including the use of protein fragments in dominant selection studies (8) . Recently, we and others (9) (10) (11) (12) have illustrated that protein (or enzyme) fragment complementation can be used in the in vivo detection of protein-protein interactions.
The detection of activity of enzymes reassembled from fragments is usually frustrated by insolubility of fragments and͞or inefficient reassembly of the fragments into native structure. We propose a strategy for the directed, noncovalent association of enzyme fragments, combined with in vivo detection of the activity: First, addition of soluble oligomerization domains to the fragments to favor their folding and assembly, via soluble linkers to allow optimal orientation for assembly. Second, an in vivo-screening assay for fragment complexation, in which lower levels of activity are needed than for detection by in vitro assays. By reconstituting enzymatic activity in a noncovalent assembly, we will have at hand a tool for answering the following questions: Do the noncovalently associated fragments allow formation of the active fold? Do the reassociated fragments allow native-like activity, with kinetics that are similar to the full-length enzyme? What effect does disruption of the sequence have on the folding and activity? And finally, can the rigidity imposed by the native covalent linkage between the fragments be replaced by the flexibility of noncovalently interacting peptides?
Here, we describe the oligomerization-assisted complementation of fragments of murine dihydrofolate reductase (mDHFR) (E.C. 1.5.1.3) as an example of dissecting an enzyme into fragments and functional reassembly of those fragments into active enzyme. DHFR has been described as comprising three structural fragments forming two domains: the adenine-binding domain (fragment 2, or F [2] ) and a discontinuous domain (F [1] and F [3] ) (13, 14) . The folate-binding pocket and the NADPHbinding groove are formed mainly by residues belonging to F [1] and F [2] . Only 4 of 29 residues that make contacts with the substrates belong to F [3] (15) , and none of these residues is directly implicated in catalysis.
Folding of fragments of Escherichia coli DHFR has revealed that only certain fragments, alone or in combination, adopt substantial secondary and tertiary structure (13) . However, circular permutation of E. coli as well as mDHFR has shown that its primary structure can be radically altered and yet yield active enzyme with native-like structure (16) . We have designed two fragments of mDHFR consisting of the sequences coding for F [1, 2] , and for F [3] , each of which is covalently linked to an interacting domain (GCN4 leucine zipper). We demonstrate the leucine zipper-dependent reassembly of catalytically active mDHFR from its fragments and examine the effects of fragment interface mutations and of active site mutations on fragment complementation. Finally, we demonstrate detection of two known protein-protein interactions in vivo, those of p21 ras GTPase with its target the ras-binding domain (RBD) of the Ser͞Thr kinase raf and the rapamycinmediated interaction of the immunophillin FKBP with the Saccharomyces cerevisiae yeast target of rapamycin (TOR2).
The strategy described here could provide a valuable tool in understanding the contribution of functional motifs to enzymatic activity and in the definition of functional building blocks that can be rationally assembled in the design of new protein catalysts. This binary association strategy ensures that the building blocks will always be brought together, regardless of their structure, in a directed and productive manner. Finally, we discuss the use of this strategy for cDNA library screening to identify protein-protein interactions or in directed evolution of proteins.
MATERIALS AND METHODS

Materials.
All reagents used were of the highest available purity. Mutagenic and sequencing oligonucleotides were purchased from GIBCO͞BRL. Restriction endonucleases and DNA-modifying enzymes were from Pharmacia and New England Biolabs. E. coli strains DH5␣ and GM2163 (dcm Ϫ ; New England Biolabs) were used for subcloning. For protein overexpression, E. coli strain BL21 carrying plasmid pRep4 (Qiagen, lac I q ) was transformed with the appropriate DNA constructs.
DNA Constructs. We constructed vectors allowing the expression of mDHFR fragments covalently linked to a hexahistidine peptide (Qiagen pQE series) and a leucine zipper (Fig. 1) . The full-length mDHFR is expressed from pQE-16. mDHFR fragments carrying their own in-frame stop codon were subcloned into pQE-32, downstream from and in-frame with the GCN4 leucine zipper-coding sequence. All final constructs were verified by DNA sequencing.
Expression Vectors Harboring the Oligomerization Domains. Residues 235-281 of the GCN4 leucine zipper (a SalI-BamHI (blunted) 254-bp fragment) were obtained from pRS316 harboring that sequence (10) . The fragment was ligated to pQE-32 linearized with SalI-HindIII (blunted). The product, construct Z, codes for: Met-Arg-Gly-Ser followed by a hexahistidine tag and 13 residues preceding the 47 GCN4 leucine zipper residues. RBD of raf were obtained by PCR amplification of pTcras and pDW333, respectively. TOR2 rapamycin-binding domain and FKBP were amplified by PCR from pMRS315 and pNH1, respectively. They were cloned respectively by XmaI-NheI and SphI-NheI in pQE32.
Creation of DHFR Fragments. The eukaryotic expression vector pMT3 harboring the mDHFR-coding sequence (17) was used as a template for PCR-generation of mDHFR containing the features allowing subcloning and separate expression of F [1, 2] and F [3] (Fig. 1) . A BspEI site at either terminus of the coding sequence, a stop codon after F [1, 2] , followed by a SpeI site for use in subcloning F [3] , were created by PCR. [1, 2, 3] coding for DHFR F [3] was subcloned into pMT3 yielding construct F [3] .
Construction of a Flexible Linker
Creation of the Expression Constructs. Fragments of constructs F [1, 2] or F [3] coding for the DHFR fragments, were subcloned into construct Z, downstream from the zippercoding sequence. The resulting constructs, Z-F [1, 2] and Z-F [3] , code for the zipper, followed by an 11 residue flexible linker and mDHFR F [1, 2] from construct Z-F [1, 2] by restriction yielding digestion and religation, construct control-F [1, 2] .
Creation of Mutants. Site-directed mutagenesis was performed on fragments of Z-F [1, 2] or Z-F [3] subcloned into pBluescript SK ϩ (Stratagene), using oligonucleotides that encode a silent mutation producing or destroying a diagnostic restriction site. Fragments of putative mutants identified by restriction were subcloned back into Z-F [1, 2] or Z-F [3] . The mutations were confirmed by DNA sequencing.
E. coli Survival Assay. Competent E. coli BL21͞pRep4 were transformed with the appropriate constructs and washed twice with M9 minimal medium before plating on M9 Petris containing 50 g͞ml kanamycin, 100 g͞ml ampicillin, and 0.5 g͞ml trimethoprim. One-half of each transformation mixture was plated in the absence and the second half in the presence of 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG). All plates were placed at 37°C for 66 hr. For the ras-raf and FKBP-TOR2 cotransformation, 80 M thymine was added to the medium. The optimal results for the FKBP-TOR2 experiments were obtained with minimal medium plates containing 1 M rapamycin (Calbiochem) and incubation at 30°C.
E. coli Growth Curves. Growth rates were determined in liquid Ma medium supplemented with ampicillin, kanamycin as well as IPTG (1 mM), and trimethoprim (1 g͞ml) where indicated. Because cells cotransformed with constructs Z-
Ile-114 3 Gly] did not form colonies when plated under selective pressure, double transformants were obtained under nonselective conditions (ϩkanamycin and ampicillin) and screening for the presence of the two constructs by restriction analysis. All experiments were performed in triplicate. Aliquots were withdrawn periodically for measurement of optical density. Doubling time was calculated for early logarithmic growth (OD 600 between 0.02 and 0.2).
Protein Overexpression and Purification. Bacteria were propagated in medium or in Terrific Broth in the presence of the appropriate antibiotics to an OD 600 of Ϸ1.0. Expression was induced by addition of 1 mM IPTG and further incubation for 24 hr if in minimal medium or 3 hr if in Terrific Broth. Small-scale denaturing and large-scale native purifications were performed on Ni-NTA agarose (Qiagen) according to the manufacturer's protocol. After native purification, imidazole was dialyzed out at 4°C against three changes of 300 vol of buffer A [100 mM potassium phosphate, pH 7.5͞1 mM phenylmethylsulfonyl fluoride͞1 mM ␤-mercaptoethanol]. As a control, untransformed cells were submitted to the same procedure for parallel enzymatic analysis.
Enzyme Assays. DHFR activity was monitored by fluorimetry, to follow tetrahydrofolate production ( exc. ϭ 310 nm; em. ϭ 360 nm). Quenching of tetrahydrofolate by DHF and NADPH was corrected for, with a tetrahydrofolate standard curve. Concentrations of substrates were determined spectrophotometrically. The reaction buffer was freshly prepared buffer A containing 10 mM ␤-mercaptoethanol. Initial rates were measured under conditions in which Ͻ15% conversion to product had occurred. For determination of specific activity, the concentration of reconstituted enzyme was estimated by methotrexate (MTX) inhibition of the DHFR activity. For the MTX-resistant Phe-31 3 Ser mutant, the concentration of enzyme present was in the range of K i (MTX) and therefore could not be determined with high accuracy. Unless otherwise indicated, the concentration of NADPH was constant at 25 M in determinations of K m (DHF) and K i (MTX). The range of MTX concentrations used in K i determinations was 100 pM-30 nM. DHF concentrations of 5 M, 10 M, and 30 M were used in Dixon representations for determination of K i (MTX) and K m (NADPH). In the indirect determination of K m (NADPH), NADPH concentrations used were 10 M, 25 M, and 50 M. All data were fitted to the Michealis-Menten equation by using the nonlinear regression analysis programs AXUM (Mathsoft, Cambridge, MA) and MACCURVE FIT (K. Raner Software, Mt. Waverley, Australia).
RESULTS
Design Considerations. mDHFR is a small (21 kDa), monomeric protein which shares high sequence identity with the human DHFR (hDHFR) sequence (91% identity) and is highly homologous to the E. coli enzyme (29% identity, 68% homology). Comparison of the crystal structures of mDHFR and hDHFR suggests that their active sites and substratebinding pockets are identical and homologous to those of E. coli DHFR (15) . The folate-binding pocket and the NADPHbinding groove are formed mainly by residues belonging to the adenine-binding domain (F [2] ) and the N-terminal portion of the discontinuous domain (F[1]) ( Fig. 2 A and B) .
Residues 101-108 of hDHFR, at the junction between F[2] and F [3] , form a disordered loop, which can be disrupted with no significant effect on activity (18) . We chose to fragment mDHFR between F[1,2] and F [3] , at residue 107, so as to cause minimal disruption of the active site and NADPH cofactorbinding sites. The native N terminus of mDHFR and the N terminus created by fragmentation occur on the same surface of the enzyme (Fig. 2 A) (15) facilitating N-terminal fusion to the leucine zipper sequences and the other oligomerizing proteins used in this study.
E. coli Survival Assays. E. coli DHFR is selectively inhibited by the anti-folate drug trimethoprim. Because mammalian DHFR has a 12,000-fold lower affinity for trimethoprim than does bacterial DHFR (19) , growth of bacteria expressing mDHFR in the presence of trimethoprim levels lethal to bacteria is an efficient means of selecting for reassembly of mDHFR fragments into an active enzyme (Fig. 1). Fig. 3A illustrates the results of cotransformation of bacteria with constructs Z-F [1, 2] and Z-F [3] in the presence of IPTG and trimethoprim, clearly showing that colony growth under selective pressure is possible only in cells expressing both fragments of mDHFR. There is no growth in cells expressing either Z-F [1, 2] or Z-F [3] alone. Oligomerization domains on both fragments of mDHFR are essential as illustrated by cotransformation of bacteria with both vectors coding for mDHFR fragments, only one of which carries a leucine zipper (Fig. 3A) and by the fact that when noninteracting oligomerization domains are tested, no growth is observed (Fig. 4) . The presence of both plasmids in bacteria grown in trimethoprim was confirmed by restriction analysis of the plasmids isolated from individual colonies and by detection of overexpression of proteins of the expected molecular weight on SDS͞PAGE of the crude lysate from Terrific Broth (data not shown).
Affinity Mutants. We made point mutations at the interface between the DHFR fragments to test first, whether reconstitution of DHFR activity is due to specific reassembly of its fragments and second, whether subtle changes in the protein stability could be detected. It could be argued that the reconstitution we observed was due to nonspecific association of F [1, 2] with F [3] ; a reduction of observed activity in the in vivo assay by site-specific mutations directed at the interface would confirm that the reconstitution is due to native-like structural reassembly. Part of the interface belongs to the hydrophobic core of DHFR. Core mutations that sequentially reduce affinity of the two fragments for each other (20) should cause a sequential reduction of response in our assay. We generated mutants of F [3] at Ile-114, whose sidechain contacts residues in F [1, 2] (Fig. 2 A) To compare the relative efficiency of reassembly of mutant mDHFR fragments into active enzyme, we measured the bacterial-doubling time in minimal medium. Doubling time under nonselective conditions was essentially constant for all transformants (Table 1) . Doubling times under selective conditions (ϩIPTG and trimethoprim) for cells expressing Z-
Ile-114 3 Ala] were 1.6-fold, 1.9-fold, and 4.1-fold higher, respectively, than the doubling time of E. coli expressing full-length mDHFR. No growth was observed for cells expressing Z-F[1,2] ϩ Z-F[3:Ile-114 3 Gly]. Cell growth was observed in the absence of induction only with the full-length mDHFR due to low level expression, whereas IPTG induction of full-length mDHFR unexpectedly prevented cell growth. Growth was partially restored by addition of the folate metabolism end-products thymine, adenine, pantothenate, glycine, and methionine (data not shown), suggesting that the overexpressed enzyme binds to and depletes the folate pool.
Methotrexate-Resistant Mutants. It could be argued that the ''affinity'' mutants reduce activity rather than fragment affinity of reassembled DHFR although Ile-114 is distant from the active site. As a further control for understanding the molecular basis for fragment reassembly, we examined other mutants, which have been previously characterized in fulllength DHFR. We mutated F[1,2] at each of five positions that significantly increase K i (MTX): Gly-15 3 Trp, Leu-22 3 Phe, Leu-22 3 Arg, Phe-31 3 Ser, and Phe-34 3 Ser. These Steady-State Kinetic Parameters of the Reconstituted Enzyme. To assess the kinetic effects of fragmentation on DHFR activity, we determined the steady-state kinetic parameters of the purified, reconstituted Phe-31 3 Ser mutant. In addition to allowing the evaluation of maintenance of MTX resistance in the reassembled enzyme, the Phe-31 3 Ser mutation has the advantage of not being susceptible to the substrate inhibition (by DHF) seen in the wild-type enzyme (23) . Binding of DHF and its competitive inhibitor MTX were first investigated. Direct determination of K m (DHF) at 25 M NADPH shows that it is in the same range as the full-length mDHFR(Phe-31 3 Ser) assayed under similar conditions (21) . This NADPH concentration is not saturating (as determined in this study; see Table 2 ); however, the high quenching by NADPH precluded measurements at saturating NADPH concentrations. Dixon plots of activity in the presence of increasing MTX concentrations, at various fixed DHF concentrations, were generated to determine K i (MTX) in a manner independent of the DHF concentrations used. K i (MTX) is in the same range as the full-length mDHFR (Phe-31 3 Ser) ( Table 2 ). The K i was not significantly affected by a 2-fold change in NADPH concentration (data not shown). As the Dixon plots showed MTX to be a true competitive inhibitor of the enzyme, V max was directly determined from the Dixon plots. From this value, k cat (substrate turnover rate) was estimated to be in the range of 6 s Ϫ1 compared with 5.5 s
Ϫ1
for mDHFR(Phe-31 3 Ser). Preliminary direct determination of K m (NADPH) resulted in a minimum estimate of 20 M; fluorescence quenching by NADPH precluded a more precise direct measurement. Therefore K m (NADPH) was determined from Dixon plots of MTX inhibition of DHF binding, at various NADPH concentrations. The V max (apparent) at each NADPH concentration could thus be precisely determined, allowing a replot of V max (apparent) vs. [NADPH] . K m (NADPH) is Ϸ3.5-fold higher than that of mDHFR(Phe-31 3 Ser) ( Table 2) . No DHFR activity was detected in untransformed bacteria treated exactly as were bacteria expressing reassembled enzyme.
Induced Hetero-Oligomerization Directed Assembly. We tested the ability of hetero-oligomerizing proteins to assist DHFR reassembly as a further illustration that complementation is general and to illustrate how the strategy can be used to detect protein-protein interactions. We studied the interactions of p21 ras GTPase with its target RBD and of the rapamycin-mediated interaction of the immunophillin FKBP with the yeast TOR2. In both cases, structures of the complexes are known, and as an added restriction, the interaction between the latter is mediated by another molecule providing a further control on oligomerization requirement for DHFR fragment assembly (24, 25) . In both cases, cell survival occurred only when complementary DHFR fragments fused to interacting proteins were expressed simultaneously and in the case of FKBP-TOR, only in the presence of effective concentrations of rapamycin (Fig. 4) . Lack of observed growth when the protein-DHFR fragment fusions were coexpressed with complementary leucine zipper-DHFR fragments further illustrates the absolute requirement of oligomerization domainassisted assembly of DHFR.
DISCUSSION
We have demonstrated that the fusion of mDHFR fragments to dimerizing proteins allows for the spatially directed, binary association of the DHFR fragments, promoted by the oligomerization-assistance of the dimerizing proteins. Detection of activity, both in vivo and in vitro, suggests that native-like folding of the fragments is promoted by their directed association.
We have shown that the rigidity imposed by the covalent linkage between residues 107 and 108 of mDHFR can be replaced by noncovalent leucine zipper interaction resulting in kinetic characteristics similar to full-length enzyme. In a similar way, cleavage of mDHFR at this loop and fusion of the native termini has produced a circularly permuted protein with physical and kinetic properties similar to the native enzyme, illustrating that radical modifications in this loop are not disruptive to activity (18) . Further, a detailed analysis of prokaryotic and eukaryotic DHFR structures has suggested that loop and subdomain movements are required for catalysis (26) . In eukaryotic DHFRs, a loop in residues 59-70 moves to stabilize interactions of DHFR with a transition state analogue. That F [1, 2] contains this region intact and the enzyme functions is consistent with this study. Further dissection of F [1, 2] into the catalytic loop and nucleotide-binding domain will aid in accessing the importance of this and other loop and secondary structure elements to catalysis. Protein domain affinity can be reduced by 1-5 kcal͞mol by changing the side chain volume in the hydrophobic core of a protein (20) .We have illustrated with the fragment interface mutations (Ile-114 and Gly-15) that with an in vivo assay we can detect and differentiate mutations that decrease fragment affinity to different degrees. By the same token, the Gly-15 3 Trp mutation is tolerated in the full-length DHFR but does not allow complementation. This result suggests that the folding and reassembly of DHFR from fragments is different from that of the full-length enzyme. The three methotrexate-resistant mutants (Leu-22 3 Phe, Leu-22 3 Arg, and Phe-31 3 Ser) centered in the substrate-binding pocket of F [1, 2] have effects consistent with characteristics in the full-length enzyme. The mutations are well tolerated and allow for very efficient fragment complementation even though they alter the kinetic parameters of the full-length enzyme relative to the wild-type. This demonstrates that mutations far from the interface can allow productive fragment association; further, we have illustrated the possibility of incorporating desirable characteristics (in this example, methotrexate resistance) into the reassembled enzyme. Phe-34 3 Ser does not allow reconstitution of activity. This may be a result of its lower solubility, or of the 5,000-fold reduction in catalytic efficiency relative to the wild-type (22) . This position is conserved in 35 of 37 natural sequences (HSSP database file:1drf.hssp) (27) and is part of a hydrophobic cluster in F [1, 2] ; it may be necessary for the proper folding or stability of this fragment.
Oligomerization domain-assisted fragment reassembly could provide a powerful strategy for enzyme dissection studies in general. The control over the assembly of separate functional domains of enzymes would permit rigorous enzymatic structure͞function studies, the definition of structural motifs, and an understanding of their role in catalysis. Detailed knowledge of the enzyme mechanism could be exploited through the combination of different functional ''building blocks'' with the functional motifs responsible for substrate binding and catalysis in other enzymes, allowing the generation of novel protein catalysts. The possibility of altering an enzyme's catalytic reaction by the combination of a substratebinding domain and an active site from different enzymes has been demonstrated recently (28) ; oligomerization domainassisted assembly offers an efficient strategy for multiple combinations of domains of interest and allows for in vivo high-throughput screening as well as in vitro characterization of products as in a directed evolution strategy (29, 30) .
There is an interesting symmetry to the system described here: the fact that the oligomerization domains are absolutely required for reconstitution means that the reconstitution of activity itself is a detector of the oligomerization domain interactions. Thus the system we describe here can be applied to studying proteinprotein interactions in vivo in a similar way as other techniques such as the yeast two-hybrid system or other fragment complementation strategies (10) (11) (12) 31) . We envisage that this application of a protein-fragment complementation assay (PCA) would have certain advantages over other approaches. Principal advantages include the fact that first, no other host-specific processes or enzymes are needed. It thus would be possible to perform selection in any cell type. We are presently pursuing variants of the DHFR PCA in yeast and mammalian cell lines (I. Remy, S.W.M., unpublished data). Secondly, the fact that the structure of the enzyme is known means that it is possible to control the way that interactions can occur. For example, to control for orientation of specifically interacting proteins by fusing them to either N or C termini of the enzyme fragments, one could discriminate between ''parallel'' vs. ''antiparallel'' interactions. Finally, the PCA strategy allows for designing a detector of variable stringency by introducing mutations that disrupt fragment complementation. We are currently pursuing the PCA strategy for stringent selection of interacting protein partners from designed libraries (J.N.P., K. Arndt, A. Plückthun, and S.W.M., unpublished data). In a more generalized application, the PCA could be used in screening cDNA libraries for proteins that interact with a known ''bait.'' The simplicity of the in vivo assay would ensure that a large number of unknowns could easily be screened for interactions.
